[Market Movement Analysis] Novavax Pharmaceuticals Soars on September 17: Cancer Vaccine + Sanofi + Vaccine Platform

1. On September 17, Moderna’s personalized cancer vaccine transactions continued, with previous data on its melanoma vaccine showing a 49% reduction in recurrence risk, and Novavax stock rose in tandem; there were no new company disclosures or trial results released that day.
2. In August, Novavax received approval for the XFG variant Nuvaxovid formulation for the 2026–2027 season, with Sanofi and Takeda responsible for commercialization. The company is eligible for related royalties and milestone payments.
3. From September 9 to 10, company management presented at a healthcare investor conference on a transformation centered on Matrix-M adjuvant licensing and cooperation; the company has already received 800 million USD in payments from partners and confirmed that the additional Sanofi milestones could reach up to 200 million USD.

(Disclaimer: This content is a summary generated from publicly available information using AI technology and is for reference only. It does not constitute investment advice.)